Abstracts tagged "SLE and rituximab"

Abstract Number: 783 • 2016 ACR/ARHP Annual Meeting
Review of SLE Cohort to Identify Predictors of Response to B Cell Depletion in Patients with Active SLE
Pedro Mota¹, Ashleigh Hennessey², Ada Ferenkeh-Koroma² and David A. Isenberg², ¹Internal Medicine, Hospital da Luz, Lisbon, Portugal, ²Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom
Background/Purpose: The use of Rituximab (RTX) has been documented via published cohort data from over 20 sites worldwide (1,2) demonstrating its useful role in the…
Abstract Number: 2695 • 2014 ACR/ARHP Annual Meeting
Alterations in B Cell Subsets and BAFF Levels in Autoimmune Rheumatic Diseases Treated with B Cell Depletion Therapy: Rituximab
Pamela M.K Lutalo¹, David P. D'Cruz² and Jo Spencer³, ¹Peter Gorer Department of Immunobiology, King's College London School of Medicine, London, United Kingdom, ²Louise Coote Lupus Unit, Guy's and St Thomas' Hospital NHS Foundation Trust, London, United Kingdom, ³Peter Gorer Department of Immunobiology, King's College London, School of Medicine, London, United Kingdom
Background/Purpose: Systemic lupus erythematosus (SLE) and granulomatosis with polyangiitis (GPA) are autoimmune diseases which develop secondary to immune self-tolerance failure. Both diseases are characterised in…
Abstract Number: 675 • 2014 ACR/ARHP Annual Meeting
Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience
Renata Aguiar¹, Ana Carolina Araújo², Ana Luisa Papoila³, Marta Alves⁴ and David Isenberg⁵, ¹Serviço de Reumatologia, Centro Hospitalar do Baixo Vouga, E.P.E., Aveiro, Portugal, ²Serviço de Medicina 2, Hospital de Curry Cabral, Centro Hospitalar Lisboa Central, Lisbon, Portugal, ³Epidemiology and Statistics Unit, Research Center of Centro Hospitalar de Lisboa Central, Centro Hospitalar Lisboa Central, Lisbon, Portugal, ⁴Epidemiology and Statistics Unit, Research Center of Centro Hospitalar de Lisboa Central, Centro Hospitalar Lisboa Central, Lisboa, Portugal, ⁵Centre for Rheumatology Research, University College Hospital London, London, United Kingdom
Background/Purpose Rituximab (RTX), an anti-CD20 chimerical monoclonal antibody, has been used as an off-label in patients with systemic lupus erythematosus (SLE) refractory to standard treatment.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].